Pharmaceutical companies have been working for years to find a drug that could break up the toxic clusters of proteins associated with Alzheimer’s disease and other neurodegenerative disorders. Many of those companies have suffered disappointingfailuresby targeting those clusters head-on. Now a Bay Area biotechnology company,Alector, is ready to try tackling...